Cargando…

Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4(+) CAR T-cell antitumor activity

CD4(+) T cells and CD4(+) chimeric antigen receptor (CAR) T cells display highly variable antitumor activity in preclinical models and in patients; however, the mechanisms dictating how and when CD4(+) T cells promote tumor regression are incompletely understood. With the help of functional intravit...

Descripción completa

Detalles Bibliográficos
Autores principales: Boulch, Morgane, Cazaux, Marine, Cuffel, Alexis, Guerin, Marion V., Garcia, Zacarias, Alonso, Ruby, Lemaître, Fabrice, Beer, Alexander, Corre, Béatrice, Menger, Laurie, Grandjean, Capucine L., Morin, Florence, Thieblemont, Catherine, Caillat-Zucman, Sophie, Bousso, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368531/
https://www.ncbi.nlm.nih.gov/pubmed/37248395
http://dx.doi.org/10.1038/s43018-023-00570-7
Descripción
Sumario:CD4(+) T cells and CD4(+) chimeric antigen receptor (CAR) T cells display highly variable antitumor activity in preclinical models and in patients; however, the mechanisms dictating how and when CD4(+) T cells promote tumor regression are incompletely understood. With the help of functional intravital imaging, we report that interferon (IFN)-γ production but not perforin-mediated cytotoxicity was the dominant mechanism for tumor elimination by anti-CD19 CD4(+) CAR T cells. Mechanistically, mouse or human CD4(+) CAR T-cell-derived IFN-γ diffused extensively to act on tumor cells at distance selectively killing tumors sensitive to cytokine-induced apoptosis, including antigen-negative variants. In anti-CD19 CAR T-cell-treated patients exhibiting elevated CAR CD4:CD8 ratios, strong induction of serum IFN-γ was associated with increased survival. We propose that the sensitivity of tumor cells to the pro-apoptotic activity of IFN-γ is a major determinant of CD4(+) CAR T-cell efficacy and may be considered to guide the use of CD4(+) T cells during immunotherapy.